PepTivator® CEF MHC Class I Plus

PepTivator® CEF MHC Class 1 Plus consists of 32 MHC-1– specific peptides of 8–12 aa in length. These sequences were derived from cytomegalovirus (HCMV), Epstein-Barr virus (EBV), and influenza virus and have been shown to elicit interferon-gamma release from CD8+ T cells in most of all individuals1,2.

In vitro stimulation of antigen-specific T cells with PepTivator Peptide Pools causes the secretion of effector cytokines and the up-regulation of activation markers, which then allow the detection and isolation of antigen-specific T cells.

... read more

Related products for PepTivator® CEF MHC Class I Plus

Product data and images for PepTivator® CEF MHC Class I Plus
Figure 1

Sequences and HLA restrictions of peptides of the PepTivator CEF MHC Class I Plus peptide pool.HLA-allele data according to www.iedb.org.

Specifications for PepTivator® CEF MHC Class I Plus
Overview

PepTivator® CEF MHC Class 1 Plus consists of 32 MHC-1– specific peptides of 8–12 aa in length. These sequences were derived from cytomegalovirus (HCMV), Epstein-Barr virus (EBV), and influenza virus and have been shown to elicit interferon-gamma release from CD8+ T cells in most of all individuals1,2.

In vitro stimulation of antigen-specific T cells with PepTivator Peptide Pools causes the secretion of effector cytokines and the up-regulation of activation markers, which then allow the detection and isolation of antigen-specific T cells.

Detailed product information
Downstream applications
  • PepTivator CEF MHC Class 1 Plus is recommended as a peptide-specific positve control for the detection of CD8+ T cells in human PBMC. This peptide set is used by the NIH. For more information refer to the NIH AIDS Research and Reference Reagent Program.
Citations for PepTivator® CEF MHC Class I Plus
Publications
  1. Currier, J. R. et al. (2002) A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J. Immunol. Methods 260 (1-2): 157-172
  2. Mwau, M. et al. (2002) Design and validation of an enzyme-linked immunospot assay for use in clinical trials of candidate HIV vaccines. AIDS Res Hum Retroviruses 18 (9): 611-618

You have previously chosen International as your location.
What do you want to do?